Abstract
Gene engineering of immune cells is a powerful tool for creating advanced and novel cellular therapies. Currently, the critical step of cellular gene editing is primarily performed using virus-based gene delivery systems. Virus-based engineering methods are commonly plagued with long lead times, inconsistent batches, low cargo capacity, and high costs. Recently, advances in the non-viral transposon-based gene engineering have provided developers with an alternative gene engineering method that addresses virus-based platform limitations. Utilizing a ‘cut-and paste’ method of gene delivery, transposon-based systems are capable of stable genomic integration. This article discusses the transposon-based TcBuster™ platform, and its competitive advantages in cell and gene engineering.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
